JP2013543862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543862A5 JP2013543862A5 JP2013538324A JP2013538324A JP2013543862A5 JP 2013543862 A5 JP2013543862 A5 JP 2013543862A5 JP 2013538324 A JP2013538324 A JP 2013538324A JP 2013538324 A JP2013538324 A JP 2013538324A JP 2013543862 A5 JP2013543862 A5 JP 2013543862A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- composition according
- agents
- pkc
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 101000971435 Oryctolagus cuniculus Protein kinase C gamma type Proteins 0.000 claims 4
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims 4
- 101710109947 Protein kinase C alpha type Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 239000003974 emollient agent Substances 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 229940035674 anesthetics Drugs 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000000043 antiallergic agent Substances 0.000 claims 2
- 239000000030 antiglaucoma agent Substances 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000003212 astringent agent Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 239000004090 neuroprotective agent Substances 0.000 claims 2
- -1 pH adjusters Substances 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003352 sequestering agent Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 238000011191 terminal modification Methods 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims 2
- 239000000080 wetting agent Substances 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 206010060932 Postoperative adhesion Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41146610P | 2010-11-08 | 2010-11-08 | |
| US41146410P | 2010-11-08 | 2010-11-08 | |
| US61/411,464 | 2010-11-08 | ||
| US61/411,466 | 2010-11-08 | ||
| PCT/IL2011/000866 WO2012063237A2 (en) | 2010-11-08 | 2011-11-08 | Buffered ophthalmic compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013543862A JP2013543862A (ja) | 2013-12-09 |
| JP2013543862A5 true JP2013543862A5 (enExample) | 2014-12-25 |
Family
ID=46051349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538324A Pending JP2013543862A (ja) | 2010-11-08 | 2011-11-08 | 眼科用緩衝組成物およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120264681A1 (enExample) |
| EP (2) | EP2944319A1 (enExample) |
| JP (1) | JP2013543862A (enExample) |
| CN (2) | CN104758921A (enExample) |
| AU (1) | AU2011327785A1 (enExample) |
| CA (1) | CA2812164A1 (enExample) |
| RU (1) | RU2013117209A (enExample) |
| WO (1) | WO2012063237A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| ES2672624T3 (es) | 2009-05-01 | 2018-06-15 | Aerie Pharmaceuticals, Inc. | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
| SG187770A1 (en) | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| RU2013117209A (ru) | 2010-11-08 | 2014-10-27 | Хилор Лтд. | Буферные глазные композиции и способы их применения |
| US20130296250A1 (en) * | 2011-01-11 | 2013-11-07 | Healor Ltd. | Method for treatment of psoriasis |
| SG10201707477SA (en) * | 2013-03-13 | 2017-10-30 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
| PT3811943T (pt) | 2013-03-15 | 2023-03-15 | Aerie Pharmaceuticals Inc | Composto para uso no tratamento de distúrbios oculares |
| CN105377285B (zh) * | 2013-04-30 | 2020-04-21 | 南加利福尼亚大学 | 通过血管紧缩素肽的加速的眼睛损伤的治愈 |
| US20150141328A1 (en) * | 2013-11-18 | 2015-05-21 | The Schepens Eye Research Institute | Stimulation of human meibomian gland function |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| US10406208B2 (en) | 2014-10-22 | 2019-09-10 | G-Treebnt Co., Ltd. | Composition containing thymosin beta 4, and pharmaceutical formulation comprising same |
| EP3011959A1 (en) | 2014-10-23 | 2016-04-27 | Santen SAS | Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha |
| CN104940904A (zh) * | 2015-05-27 | 2015-09-30 | 北京爱特普科技有限公司 | 一种腔体粘膜微生态调节剂及其制备方法 |
| KR20170021667A (ko) * | 2015-08-18 | 2017-02-28 | 주식회사 지트리비앤티 | 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물 |
| US9867868B2 (en) * | 2015-08-18 | 2018-01-16 | G-Treebnt Co., Ltd. | Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid |
| CN108472312A (zh) | 2015-09-28 | 2018-08-31 | 阿祖拉眼科有限公司 | 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 |
| CA3019349A1 (en) | 2016-04-14 | 2017-10-19 | Azura Ophthalmics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| JP6943707B2 (ja) * | 2016-08-23 | 2021-10-06 | 積水化学工業株式会社 | 水溶性樹脂組成物及び水溶性樹脂フィルム |
| MX2019002396A (es) * | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
| US10918699B2 (en) | 2017-03-22 | 2021-02-16 | Michael C. Struck | Therapeutic treatment for neurotrophic keratopathy |
| BR112019020078A2 (pt) | 2017-03-31 | 2020-04-28 | Aerie Pharmaceuticals Inc | compostos e composições farmacêuticas à base de arilciclopropil-amino-isoquinolinil amida e métodos de uso dos mesmos |
| CA3079544A1 (en) | 2017-10-19 | 2019-04-25 | Mona E. Buice | Topical composition for improved healing of open wounds |
| CA3112391A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| JP2020075918A (ja) * | 2018-11-02 | 2020-05-21 | 千寿製薬株式会社 | 角膜上皮創傷治癒促進用の眼科用組成物 |
| JP2022521273A (ja) * | 2019-02-20 | 2022-04-06 | エレオス ファーマシューティカルズ エルエルシー | 眼の病気の治癒の改善のための局所用組成物 |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| CA3166357A1 (en) | 2020-01-10 | 2021-07-15 | Azura Ophthalmics Ltd. | Instructions for composition and sensitivity |
| CN111610334A (zh) * | 2020-05-18 | 2020-09-01 | 山东省肿瘤防治研究院（山东省肿瘤医院） | 一种基于细胞大小过滤识别肿瘤患者外周血循环肿瘤细胞的方法 |
| CN118340775A (zh) * | 2023-01-09 | 2024-07-16 | 维眸生物科技(浙江)有限公司 | 一种含vvn539的眼用组合物及其用途 |
| WO2025175150A1 (en) * | 2024-02-16 | 2025-08-21 | Allergan, Inc. | Enhanced artificial tear formulations |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549747A (en) | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| US3947573A (en) | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
| US3856919A (en) | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767788A (en) | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767789A (en) | 1971-06-21 | 1973-10-23 | Burton Parsons & Co Inc | Method of providing a synthetic mucus in vivo |
| US3987163A (en) | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
| US3907985A (en) | 1973-07-27 | 1975-09-23 | Burton Parsons And Company Inc | Polystyrene sulfonate containing opthalmic solutions |
| US4029817A (en) | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
| US3920810A (en) | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
| US4120949A (en) | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| CA2125060C (en) | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| JP3059092B2 (ja) * | 1995-11-15 | 2000-07-04 | 田辺製薬株式会社 | ドライアイおよびドライアイを原因とする疾患の予防・治療剤 |
| US20060258562A1 (en) | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| NZ545318A (en) * | 2003-07-15 | 2009-06-26 | Univ Bar Ilan | Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor |
| CA2535029C (en) * | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| US8367606B2 (en) * | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
| ITMI20052036A1 (it) * | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato |
| WO2008048675A2 (en) * | 2006-10-20 | 2008-04-24 | Celldex Therapeutics, Inc. | Treatment for age-related macular degeneration and other diseases of the eye |
| US20080292726A1 (en) * | 2007-01-23 | 2008-11-27 | Bernstein Lawrence R | Ophthalmic gallium compositions and methods of their use |
| WO2008137118A1 (en) * | 2007-05-04 | 2008-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Suppression of inflammation associated with transplantation using an epsilon pkc inhibitor |
| NZ582556A (en) * | 2007-07-30 | 2013-02-22 | Healor Ltd | Pharmaceutical composition for treating wounds and related methods |
| CA2698013A1 (en) * | 2007-08-27 | 2009-03-05 | Kai Pharmaceuticals, Inc. | Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| US8506944B2 (en) * | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| CA2726161C (en) * | 2008-06-19 | 2015-09-08 | Kinki University | A peptide derivative and a composition for promoting lacrimal secretion comprising the same |
| WO2010029350A1 (en) * | 2008-09-09 | 2010-03-18 | University Of East Anglia | Treatment of fibrotic eye disorders |
| EP2523677A2 (en) * | 2010-01-11 | 2012-11-21 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| RU2013117209A (ru) | 2010-11-08 | 2014-10-27 | Хилор Лтд. | Буферные глазные композиции и способы их применения |
-
2011
- 2011-11-08 RU RU2013117209/15A patent/RU2013117209A/ru not_active Application Discontinuation
- 2011-11-08 CN CN201510134566.8A patent/CN104758921A/zh active Pending
- 2011-11-08 WO PCT/IL2011/000866 patent/WO2012063237A2/en not_active Ceased
- 2011-11-08 AU AU2011327785A patent/AU2011327785A1/en not_active Abandoned
- 2011-11-08 EP EP15167715.0A patent/EP2944319A1/en not_active Withdrawn
- 2011-11-08 EP EP11840613.1A patent/EP2637684A4/en not_active Withdrawn
- 2011-11-08 CA CA2812164A patent/CA2812164A1/en not_active Abandoned
- 2011-11-08 JP JP2013538324A patent/JP2013543862A/ja active Pending
- 2011-11-08 US US13/291,553 patent/US20120264681A1/en not_active Abandoned
- 2011-11-08 CN CN2011800544664A patent/CN103249429A/zh active Pending
-
2014
- 2014-08-14 US US14/459,376 patent/US20150094260A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543862A5 (enExample) | ||
| RU2013117209A (ru) | Буферные глазные композиции и способы их применения | |
| ES2335437T3 (es) | Composiciones farmaceuticas oftalmicas a base de aminoacidos y de hialuronato de sodio. | |
| JP2007526316A (ja) | 疾患を処置するための組成物および方法 | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2006503044A (ja) | 創傷の処置におけるラクトフェリン | |
| RU2008136324A (ru) | Желудочно-кишечный пролиферативный фактор и его применения | |
| WO2007106381A3 (en) | Ophthalmic compositions comprising povidone-iodine | |
| RU2010141542A (ru) | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций | |
| RU2011109084A (ru) | Терапевтические композиции, содержащие мацитентан | |
| US20250000790A1 (en) | Ketorolac compositions for corneal wound healing | |
| JP5421910B2 (ja) | ペプチド誘導体およびそれを含む涙液分泌促進組成物 | |
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| RU2017118405A (ru) | Новое лечение роговицы с применением ламинина | |
| CA2785851A1 (en) | Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction | |
| TR201908487T4 (tr) | Oftalmolojik bileşimler ve kullanımları. | |
| JP4653516B2 (ja) | 涙液分泌促進ペプチドおよびその組成物 | |
| CN106488773B (zh) | Apc类似物用于创伤愈合的用途 | |
| US20100227868A1 (en) | Treatment methods with brimonidine | |
| RU2004105844A (ru) | Новое применение 2-[5-(4-фторфенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей | |
| CA3104843C (en) | Dosing regimens for treating hypoxia-associated tissue damage | |
| WO2021156857A1 (en) | Compositions comprising amelogenin and uses thereof | |
| JP6748339B2 (ja) | フィナフロキサシンおよびトリスを含む組成物 | |
| EA201490173A1 (ru) | Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции | |
| US20190380985A1 (en) | Composition Containing N-acetyldiaminobutyric Acid |